MabCure Inc. (OTCBB: MBCI)

MabCure Inc. is a biotechnology company using a “re-engineered” Hybridoma methodology to create monoclonal antibodies (Mabs) for the detection of cancer at an early stage, where the cure rates are greater than 90%. MabCure has already generated highly specific Mabs against three human malignancies: melanoma, ovarian, and prostate cancers.

Unlike all other commercially available “anti-cancer” antibodies, MabCure’s Mabs uniquely target only cancer cells. These Mabs will first serve for the detection of early stage cancers and later as candidates for cancer imaging and for the development of cancer-specific drugs devoid of toxicity.

There are no blood tests or useful imaging methods that can adequately and routinely detect most types of cancers when they are at their earliest and most curable stage. MabCure’s vision is to change the reality of cancer as a largely incurable disease.